Physician

Mark S. Rubin, M.D.

According to 2025 Medicare claims, Mark Rubin, M.D. (NPI: 1033192570) practices hematology/oncology in the Naples-Marco Island, FL market, with the plurality of this provider's patient population coming from Collier, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34135-4773.

Rubin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,397 traditional Medicare patients, billed 464,669 HCPCS/CPT codes, and received $8,674,303 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,628 prescription claims across 325 beneficiaries totaling $6,765,027 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 11 claims. Open Payments data shows 37 records totaling $783. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $5,045,256 to $8,674,303. Similarly, Part D prescription costs have risen steadily, from $2,819,743 to $6,765,027. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,915	512,909	$5,045,256
2016	1,726	512,078	$5,373,139
2017	1,832	513,457	$6,241,839
2018	1,612	553,120	$6,206,486
2019	1,615	611,135	$7,048,162
2020	1,510	607,011	$9,729,321
2021	1,349	529,129	$8,036,435
2022	1,448	438,608	$7,537,458
2023	1,323	470,975	$7,614,036
2024	1,397	464,669	$8,674,303

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	357	1,829	$2,819,743
2016	361	1,755	$3,742,265
2017	379	1,995	$4,166,916
2018	360	1,782	$4,091,317
2019	394	1,776	$4,946,319
2020	411	2,046	$5,062,608
2021	400	1,909	$6,324,407
2022	337	1,625	$6,088,663
2023	299	1,434	$5,384,694
2024	325	1,628	$6,765,027

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	80	631	$75,100
2016	58	400	$42,739
2017	12	132	$26,068
2018	33	177	$24,834
2019	N/R	108	$13,112
2020	40	227	$19,786
2021	N/R	118	$9,390
2022	N/R	28	$789
2023	N/R	11	$891
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	823	2,546	$99
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	413	604	$70
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	759	1,956	$13
36415	Insertion of needle into vein for collection of blood sample	1,010	3,923	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	988	4,110	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	63	1,764	$1,019,261
Tagrisso	Osimertinib Mesylate	41	1,230	$653,877
Ibrance	Palbociclib	30	840	$484,321
Xtandi	Enzalutamide	39	1,410	$477,759
Venclexta	Venetoclax	35	1,048	$408,092

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	36	$783	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	1	$1,616,764	Catalyst Orthoscience

Explore More Providers

FAQ

What Medicare data is available for Mark S. Rubin, M.D.?

Tedicare shows public-source Medicare data for Mark S. Rubin, M.D. (NPI 1033192570), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark S. Rubin, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark S. Rubin, M.D.?

Mark S. Rubin, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Mark S. Rubin, M.D. have Open Payments data?

Mark S. Rubin, M.D. has 37 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.